Zynerba Pharmaceuticals, Inc. Price Today
Zynerba Pharmaceuticals, Inc.
ZYNE
Healthcare
$70.12M
💰
Market Cap
0
💸
Price to Earnings
$-0.8
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Hold Consensus
Buy |
0 |
Strong Buy |
0 |
Hold |
6 |
Sell |
1 |
Strong Sell |
2 |
ZYNE Price Forecast Target
1.3 👉 1.4 +8%
ZYNE EPS Forecast
-0.8 👉 -0.6 +-28%
Financials
Profit Margin
0 %
Revenue Growth
0 %
Dividend
$ 0
Held Percent
6.1% - Insiders
12.1% - Institutions
81.8% - Public
Major Fund Holders
-
💰 Vanguard Group Inc $710,549.0
-
💰 Blackrock Inc. $241,410.0
-
💰 ETF Managers Group, LLC $310,954.0
-
💰 Renaissance Technologies, LLC $224,846.0
-
💰 Geode Capital Management, LLC $126,274.0
Stock Ideas
Bill Ackman Portfolio
Bill Ackman, a renowned investor, has established himself as a long-term value investor with a keen eye for short-term price fluctuations. His expertise lies in special situations investments, and his Pershing Square portfolio reflects a highly conc…
Jim Chanos Portfolio
Jim Chanos is a revered figure in the world of portfolio management, known for his expertise in short selling and his pivotal role in uncovering fraud at Enron and WorldCom. Hailing from Milwaukee and a graduate of Yale with an economics degree, Ch…
Seth Klarman Portfolio
Seth Klarman's investment prowess is exemplified by his exceptional track record. Since the inception of his fund until 2008, he achieved an impressive compound return-on-investment of 20%. This remarkable achievement showcases his astute investment…
Andreas Halvorsen Portfolio
Andreas Halvorsen is a Norwegian billionaire investor, hedge fund manager, and the founder of Viking Global Investors, a large hedge fund with over $50 billion in assets under management. He is known for his long-term, value-oriented investment appr…📮FAQ
Some Frequently Asked Questions.
The Zynerba Pharmaceuticals, Inc. industry is Drug Manufacturers—Specialty & Generic
The Zynerba Pharmaceuticals, Inc. sector is Healthcare
The Zynerba Pharmaceuticals, Inc. forecasted predicted Price to Earnings PE ratio is -2.3
The Zynerba Pharmaceuticals, Inc. Price to Earnings PE ratio is 0
The Market Capitalization of Zynerba Pharmaceuticals, Inc. is $70.12M
There are total of 35451484 float shares with 12.1% held by Institutions and 6.1% held by insiders
The MZynerba Pharmaceuticals, Inc. forecasted Earnings per Share EPS is $-0.6
The Zynerba Pharmaceuticals, Inc. Earnings per Share EPS is -0.8
The Zynerba Pharmaceuticals, Inc. company has $0 gross profits with 0 profit margins
The Zynerba Pharmaceuticals, Inc. Earnings Growth is 0% with 0% quarterly earnings growth
The Zynerba Pharmaceuticals, Inc. Revenue is $0 with 0 revenue growth
The price target for Zynerba Pharmaceuticals, Inc. stock is $1.4 for the high target and $1.1 for the low target
The consensus analyst recommendations for Zynerba Pharmaceuticals, Inc. is Hold, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Zynerba Pharmaceuticals, Inc. is Hold, with the following breakdown:
- Buy: 0
- Strong Buy: 0
- Hold: 6
- Sell: 1
- Strong Sell: 2
The Beta of Zynerba Pharmaceuticals, Inc. is 1.2
The dividend of Zynerba Pharmaceuticals, Inc. is $0
The dividend yield of Zynerba Pharmaceuticals, Inc. is 0%
The biggest institutional and mutual fund holders of Zynerba Pharmaceuticals, Inc. stock are
- Vanguard Group Inc
- Blackrock Inc.
- ETF Managers Group, LLC
- Renaissance Technologies, LLC
The Zynerba Pharmaceuticals, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0